Biofrontera has successfully completed a first human trial with its migraine prophylaxis compound BF-1
Leverkusen, Germany – Biofrontera announced today that it has successfully completed a first human trial with its migraine prophylaxis compound BF-1.
The study revealed that Biofrontera’s development compound has excellent pharmacokinetic properties. After oral application the compound was absorbed completely from the digestive tract of healthy volunteers within few hours. In addition, the half-life of the compound was determined to be longer than 24 hours.
This important result indicates that the development of a standard formulation for a convenient once daily tablet is feasible.
BF-1 is the leading product of Biofrontera’s maturing preclinical product portfolio of anti-inflammatory drugs. Biofrontera develops the potent and highly specific 5-HT2B receptor blocker for the prophylactic treatment of severe migraine.
“We believe that migraine prophylaxis is a potential block-buster market. A drug like BF-1, which we expect to be effective in migraine prophylaxis without any relevant adverse side effects, should therefore be an interesting product for a large pharmaceutical company. Since it is outside of our dermatology focus, we intend to license it to a big company after the demonstration of its efficacy in patients. The results of the current clinical trial are so exciting because most drugs fail due to pharmacokinetic problems. With such excellent pharmacokinetic properties the overall chance of a successful development of BF-1 is greatly increased,” commented Prof. Dr. Hermann Lübbert, Biofrontera’s CEO.
Migraines are acute, periodically occurring attacks of very severe headache, usually affecting only one side of the head and often accompanied by nausea and vomiting. It is estimated that approximately 10-12% of the population in industrialized countries suffer from migraine attacks. Biofrontera believes that prophylactic treatment is indicated for the 10-20% of the patients with frequent attacks.
About Biofrontera AG
Biofrontera AG is specialized in the development of pharmaceutical products in the area of dermatology. The company is characterized by a broad, relatively close to the market product portfolio and a solid liquidity. Biofrontera is listed in the regulated market of the Düsseldorf stock exchange under the symbol B8F and the ISIN number DE0006046113.
This notification contains certain future-related statements based on present assumptions and forecasts made by Biofrontera AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company/the Biofrontera group and the estimates and expectances given here. Biofrontera assumes no liability whatsoever to update these future-related statements or to conform them to future events or developments.
- Contact Information
- Anke zur Mühlen
- Corporate Communication
- Biofrontera AG
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.